RxDoctor Payments Data

Eric Schwaber

Internal Medicine · Milford, CTNPI 1528598364

Payments from drug & device makers

$6,491in general payments, 2019–2025

Across 55 payments — averaging $118.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$5K
  • AbbVie$424
  • Inspire Medical Systems, Inc.$291
  • Novo Nordisk$113
  • Exact Sciences$73
  • AstraZeneca$67
  • plus $63 from 3 others

What the payments were for

  • Consulting fees$5,40083%
  • Food & beverage$1,09117%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,491 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$303,506
Medicare patients
378
Services billed
4,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$173,079
MounjaroTirzepatide75$94,409
EliquisApixaban60$86,778
OzempicSemaglutide61$77,868
RybelsusSemaglutide15$35,184
MyrbetriqMirabegron37$24,907
JanuviaSitagliptin Phosphate16$21,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$19,446
FarxigaDapagliflozin Propanediol15$17,335
Breo ElliptaFluticasone/Vilanterol26$14,329
TrulicityDulaglutide13$13,073
Arnuity ElliptaFluticasone Furoate51$11,506
Serevent DiskusSalmeterol Xinafoate15$8,396
Janumet XrSitagliptin Phos/Metformin Hcl12$7,851
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$113$113,05276 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$5,460$45,28294 claims
AstraZenecaFarxiga$67$17,33515 claims
AbbVieSynthroid$424$4,32657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →